CHAPTER 6. RADIONUCLIDE THERAPY
494
BIBLIOGRAPHY TO SECTION 6.12
GUHLKE, S., et al., Stabilization of rhenium-188 and iodine-131 labelled peptides for
radiotherapy, Eur. J. Nucl. Med. 24 (1997) 1059(A).
KRENNING, E.P., et al., Somatostatin receptor: Scintigraphy and radionuclide therapy,
Digestion 57 Suppl. (1996) 57–61.
LOEVINGER, R., BUDINGER, T., WATSON, E., MIRD Primer for Absorbed Dose
Calculations, Society of Nuclear Medicine, Reston, VA (1998).
OTTE, A., et al., DOTATOC: A powerful new tool for receptor-mediated radionuclide
therapy, Eur. J. Nucl. Med. 24 (1997) 792–795.
OTTE, A., et al., Yittrium-90-labelled somatostatin-analogue for cancer treatment,
Lancet 351 (1998) 417–418.
SMITH-JONES, P., et al., DOTA-lanreotide: A novel somatostatin analogue for tumor
diagnosis and therapy, Endocrinology 140 11 (1999) 5136–5148.
STABIN, M.G., MIRDOSE personal computer software for internal dose assessment in
nuclear medicine, J. Nucl. Med. 37 (1996) 538–546.
VIRGOLINI, I., et al., Indium-111-DOTA-lanreotide: Biodistribution, safety and
radiation absorbed dose in tumour patients, J. Nucl. Med. 39 (1998) 1928–1936.
6.13. RADIOIMMUNOTHERAPY
6.13.1. Introduction
Radioimmunotherapy is a treatment modality, currently under investi-
gation, which uses radiolabelled antibodies in the therapy of cancer. This
section provides an overview of the current status of radioimmunotherapy and
outlines the practical considerations.
6.13.2. Physiological basis
Monoclonal antibodies against a variety of tumour associated antigens
have been developed and shown to target tumours with minimal side effects.
Numerous radionuclides have been conjugated to antibodies and the radio
-
immunoconjugates have been shown to be stable in vivo.